Corporate Action (Buyback Consideration)
Zydus Lifesciences Promoters to Participate in ₹1,100 Crore Buyback
NSE
zyduslife
BSE
532321
Zydus Lifesciences Limited informed exchanges that members of the promoter group and persons in control of the company have communicated their intention to participate in the company’s ₹1,100 crore share buyback announced earlier. The buyback will be conducted through the tender offer route at ₹1,150 per equity share.
PRICE-SENSITIVE TRIGGER
Event: Promoter group communicated intention to participate in the company’s buyback offer.
Type: Corporate Action (Buyback Consideration)
Impact: Positive
Immediate Effect: The update provides clarity on promoter participation in the buyback process and reinforces management confidence in the company.
Key Metrics:
- Total Buyback Size: ₹1,100 crore
- Buyback Price: ₹1,150 per equity share
- Maximum Shares to be Bought Back: 95,65,217 equity shares
- Buyback Size as % of Equity Capital: 0.95%
- Face Value per Share: ₹1
Highlight Metric:
- Zydus Lifesciences announced a ₹1,100 crore buyback at ₹1,150 per share.
What Happened ?
Zydus Lifesciences Limited informed stock exchanges that members of the promoter group and persons in control of the company have expressed their intention to participate in the buyback announced by the board earlier on May 19, 2026.
The buyback will be executed through the tender offer route under applicable SEBI Buyback Regulations and Companies Act provisions.
Promoters may tender shares up to their respective shareholding or a lower number of shares as permitted under law.
Key Details
Buyback Structure:
- Buyback approved for up to 95,65,217 equity shares.
- Buyback price fixed at ₹1,150 per equity share.
- Aggregate buyback amount capped at ₹1,100 crore.
- Buyback will be undertaken via tender offer route.
Promoter Participation:
- Promoter group members communicated their intention to participate.
- Persons in control of the company may tender shares in the offer.
- Participation will be subject to applicable laws and regulations.
Regulatory Framework:
- Buyback will comply with:
- SEBI Buy-back of Securities Regulations, 2018
- Companies Act, 2013
- Other applicable legal provisions
Note:
- The company clarified that promoters may tender their full eligible shareholding or a lower quantity depending on applicable provisions.
Risk Analysis
Key Risks:
- Buyback participation may reduce public float marginally.
- Market volatility may affect post-buyback stock performance.
- Regulatory timelines and procedural compliance may impact execution.
- Investors expecting larger buyback acceptance ratios may face disappointment.
Worst Case Scenario:
- Weak market sentiment or lower-than-expected participation/acceptance may limit positive impact on stock performance.
Risk Level: Low
Company Commentary
- Promoter group members have communicated their intention to participate in the buyback.
- Buyback will be conducted through the tender offer route.
- The aggregate buyback size will not exceed ₹1,100 crore.
- Equity shares will be bought back at ₹1,150 per share.
Official Exchange Filing: Zydus Lifesciences Limited